Models of neurotoxicity: Extrapolation of benchmark doses in vitro

Risk Analysis

Volumn 23, Issue 3, 2003, Pages 505-514

  Goldoni, Matteo ^a   Vettori, Maria Vittoria ^a   Alinovi, Rossella ^a   Caglieri, Andrea ^a   Ceccatelli, Sandra ^b   Mutti, Antonio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Benchmark dose; Manganese; Methyl mercury; Neurotoxicity in vitro; Styrene oxide

Indexed keywords

BENCHMARKING; CELLS; EPIDEMIOLOGY; MATHEMATICAL MODELS;

NEUROTOXICITY;

RISK ASSESSMENT;

MANGANESE CHLORIDE; METHYLMERCURY; NEUROTOXIN; STYRENE OXIDE;

TOXICITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BENCHMARK DOSE; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CURVE FITTING; DOSE RESPONSE; DOSIMETRY; EPIDEMIOLOGICAL DATA; HUMAN; HUMAN CELL; IN VITRO STUDY; MATHEMATICAL MODEL; NEUROTOXICITY; NONHUMAN; RISK ASSESSMENT;

ANIMALS; CELL LINE; CELL SURVIVAL; CHLORIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; HUMANS; MANGANESE COMPOUNDS; METHYLMERCURY COMPOUNDS; MODELS, BIOLOGICAL; NEUROTOXINS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RISK ASSESSMENT; STEREOISOMERISM;

EID: 0037976885     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1111/1539-6924.00331     Document Type: Article

References (46)

1. Harry, G., Billingsley, M., Bruinink, A., et al. (1998). In vitro techniques for the assessment of neurotoxicity. Environmental Health Perspectives, 106, 31-58.
2. Blaauboer, B., Balls, M., Barratt, M., et al. (1998). 13th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): Alternative testing methodologies and conceptual issues. Environmental Health Perspectives, 106, 413-415.
3. Blaauboer, B. (2001). Toxicodynamic modelling and the interpretation of in vitro toxicity data. Toxicology Letters, 120, 111-123.
4. Flint, O. (1999). An introduction to the practical applications of new in vitro tests. In V. Pentreath (Ed.), Neurotoxicology in vitro (pp. 3-16). Philadelphia, PA: Taylor & Francis.
5. Parker, T., & Clothier, R. (1999). Assessment of toxicant-induced damage. In V. Pentreath (Ed.), Neurotoxicology in vitro (pp. 43-75). Philadelphia, PA: Taylor & Francis.
6. Tardiff, R., & Rodricks, J. (1987). Comprehensive risk assessment. In R. Tardiff & J. Rodricks (Eds.), Toxic substances and human risk - Principles of data interpretation (pp. 391-430). New York: Plenum Press.
7. Rabovsky, J., Fowles, J., Hill, M., & Lewis, D. (2001). A health benchmark for the neurologic effects of styrene: Comparison with NOAEL/LOAEL approach. Risk Analysis, 21, 117-126.
8. Crump, K. (1984). A new method for determining allowable daily intakes. Fundamental and Applied Toxicology, 4, 854-871.
9. Murrell, J., Portier, C., & Morris, R. (1998). Characterizing dose-response I: Critical assessment of the benchmark dose concept. Risk Analysis, 18, 13-26.
10. Allen, B., Kavlock, R., Kimmel, C., & Faustman, E. (1994). Dose-response assessment for developmental toxicity II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundamental and Applied Toxicology, 23, 487-495.
11. Allen, B., Kavlock, R., Kimmel, C., & Faustman, E. (1994). Dose-response assessment for developmental toxicity III. Statistical models. Fundamental and Applied Toxicology, 23, 496-509.
12. Gephart, L., Salminen, W., Nicolich, M., & Pelekis, M. (2001). Evaluation of subchronic toxicity data using the benchmark dose approach. Regulatory Toxicology and Pharmacology, 33, 37-59.
13. Gaylor, D. E., & Slikker, W. J. (1990). Risk assessment for neurotoxic effects. Neurotoxicology, 11, 211-218.
14. Crump, K. (1995). Calculation of benchmark doses from continuous data. Risk Analysis, 15, 79-89.
15. Gaylor, D., & Chen, J. (1996). Precision of benchmark dose estimates for continuous (nonquantal) measurements of toxic effects. Regulatory Toxicology and Pharmacology, 24, 19-23.
16. Gaylor, D., Ryan, D., Krewski, D., & Zhu, Y. (1998). Procedures for calculating benchmark doses for health risk assessment. Regulatory Toxicology and Pharmacology, 28, 150-164.
17. Kalliomaa, K., Haag-Gronlund, M., & Victorin, K. (1998). A new model function for continuous data sets in health risk assessment of chemical using the benchmark dose concept. Regulatory Toxicology and Pharmacology, 27, 98-107.
18. West, R., & Kodell, R. (1999). A comparison of methods of benchmark-dose estimation for continuous response data. Risk Analysis, 19, 453-459.
19. DeLean, A., Munson, P., & Rodbard, D. (1978). Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. American Journal of Physiology, E97-E102.
20. Meddings, J., Scott, R., & Fick, G. (1989). Analysis and comparison of sigmoidal curves: Application to dose-response data. American Journal of Physiology, 257, 982-989.
21. Poch, G., & Pancheva, S. (1995). Calculating slope and ED50 of additive dose-response curves and application of these tabulated parameters values. Journal of Pharmacological and Toxicological Methods, 33, 137-145.
22. Poch, G., Vychodil-Kahr, S., & Petru, E. (1999). Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing. Int. J. Clin. Pharmacol. Therap., 37, 189-192.
23. Levasseur, L., Slocum, H., Rustum, Y., & Greco, W. (1998). Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Research, 58, 5749-5761.
24. Gardner, S. (2000). A mechanistic, predictive model of dose- response curves for cell cycle phase-specific and -nonspecific drugs. Cancer Research, 60, 1417-1425.
25. Kohn, J., Minotti, S., & Durham, H. (1995). Assessment of neurotoxicity of styrene, styrene oxide and styrene glycol in primary cultures of motor and sensory neurons. Toxicology Letters, 75, 29-37.
26. Mossman, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
27. Hill, A. (1910). The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. Journal of Physiology, 40, iv-vii.
28. Van Holde, K. (1985). Physical biochemistry (2nd ed.). Englewood Cliffs, NJ: Prentice-Hall, Inc.
29. Vettori, M., Gatti, R., Orlandini, G., et al. (1999). An in vitro model for the assessment of manganese neurotoxicity. Toxicology in Vitro, 13, 931-938.
30. Malecki, E. (2001). Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons. Brain Research Bulletin, 55, 225-228.
31. Di Lorenzo, D., Ferrari, F., Agrati, R, et al. (1996). Manganese effects on the human neuroblastoma cell line SK-ER3. Toxicology and Applied Pharmacology, 140, 51-57.
32. Sanfeliu, C., Sebastià, J., & Kim, S. (2001). Methylmercury neurotoxicity in cultures of human neurons, astrocytes, neuroblastoma cells. Neurotoxicology, 22, 317-327.
33. Gregotti, C., Kirby, Z., Manzo, L., Costa, L., & Faustman, E. (1994). Effects of styrene oxide on differentiation and viability of rodent embryo cultures. Toxicology and Applied Pharmacology, 128, 25-35.
34. Pagano, D., Yagen, B., Hernandez, O., Bend, J., & Zeiger, E. (1982). Mutagenicity of (R) and (S) styrene 7,8-oxide and the intermediary mercapturic acid metabolites formed from styrene 7,8-oxide. Environmental Mutagenesis, 4, 575-584.
35. Seiler, J. (1990). Chirality-dependent DNA reactivity as the possible cause of the differential mutagenicity of the two components in an enantiomeric pair of epoxides. Mutation Research, 245, 165-169.
36. Takeda, A., Sawashita, J., & Okada, S. (1998). Manganese concentration in rat brain: Manganese transport from the peripheral tissues. Neuroscience Letters, 242, 45-48.
37. Pappas, B., Zhang, D., Davidson, C., Crowder, T., Park, G., & Fortin, T. (1997). Perinatal manganese exposure: Behavioral, neurochemical, and histopathological effects in the rat. Neurotoxicology and Teratology, 19, 17-25.
38. Ingersoll, R., Montgomery, J., Vasken, E. B., & Aposhian, H. (1995). Central nervous system toxicity of manganese I. Inhibition of spontaneous motor activity in rats after intrathecal administration of manganese chloride. Fundamental and Applied Toxicology, 27, 106-113.
39. Bird, E., Anton, A., & Bullock, B. (1984). The effect of manganese inhalation on basal ganglia dopamine concentrations in rhesus monkey. Neurotoxicology, 5, 59-66.
40. Carrier, G., Brunet, R., Caza, M., & Bouchard, M. (2001). A toxicokinetic model for predicting the tissue distribution and elimination of organic and inorganic mercury following exposure to methyl mercury in animals and humans. I. Development and validation of the model using experimental data in rats. Toxicology and Applied Pharmacology, 171, 38-49.
41. Willes, R. (1977). Tissue distribution as a factor in species susceptibility to toxicity and hazard assessment. Example: Methylmercury. Journal of Environmental Pathology and Toxicology, 1, 135-146.
42. Cernichiari,E., Brewer, R., Myers, G., et al. (1995). Monitoring methylmercury during pregnancy: Maternal hair predicts fetal brain exposure. Neurotoxicology, 16, 705-710.
43. Rossi, A., Ahlbom, E., Ogren, S., Nicotera, P., & Ceccatelli, S. (1997). Prenatal exposure to methylmercury alters locomotor activity of male but not female rats. Experimental Brain Research, 117, 428-436.
44. Petersson, K., Dock, L., Soderling, K., & Vahter, M. (1991). Distribution of mercury in rabbits subchronically exposed to low levels of radiolabeled methyl mercury. Pharmacology and Toxicology, 68, 464-468.
45. ACGIH. (1997). Threshold limit values for chemical substances and physical agents and biological exposure index (6th ed.). Cincinnati, OH: American Conference of Governmental Industrial Hygienist.
46. Savolainen, H. (1978). Accumulation of styrene monomer and neurochemical effects of long-term inhalation exposure in rats. Scandinavian Journal of Work Environment and Health, 4(2), 78-83.